Now showing items 1-3 of 3

    • Biodegradable Polymersomes for the Delivery of Gemcitabine to Panc-1 Cells. 

      Evans, Sydney M; Frail, PR; Hammer, DA; Jenkins, WT; Katz, JS; Koch, CJ; Shah, NN; ... (10 authors) (J Pharm (Cairo), 2017-03-01)
      Traditional anticancer chemotherapy often displays toxic side effects, poor bioavailability, and a low therapeutic index. Targeting and controlled release of a chemotherapeutic agent can increase drug bioavailability, mitigate ...
    • Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. 

      Clay, TM; Kemper, Alex Randall; Koeberl, Dwight D; Luo, X; Osada, Takuya; Rodriguiz, Ramona M; Sun, Baodong; ... (9 authors) (Hum Gene Ther, 2012-05)
      Pompe disease can be treated effectively, if immune tolerance to enzyme replacement therapy (ERT) with acid α-glucosidase (GAA) is present. An adeno-associated viral (AAV) vector carrying a liver-specific regulatory cassette ...
    • X-Ray Psoralen Activated Cancer Therapy (X-PACT). 

      Adamson, Justus D; Alcorta, DA; Beyer, WF; Dewhirst, Mark Wesley; Dodd, RD; Fathi, Z; Fecci, Peter Edward; ... (20 authors) (PLoS One, 2016)
      This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative ...